Ollie Hinkle Heart Foundation will Introduce Ventripoint's AI-Heart-Imaging Diagnostic Technology to America's Hospitals

 Toronto, Ontario – TheNewswire - December 05, 2023 – One of the United States’ leading foundations, the Ollie Hinkle Heart Foundation (OHHF), has selected Ventripoint’s AI-powered heart-imaging technology as one of three artificial intelligence systems it will be presenting to U.S. hospitals. 

 Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has pioneered an AI technology that transforms ultrasound scans into MRI-quality images of the heart in minutes, at a fraction of the cost, making it a new alternative to MRI heart scans.   

 Ventripoint’s FDA-cleared AI-heart-imaging technology can be easily used with all brands of cardiac ultrasound equipment. Technicians and medical staff can be trained on the unit in approximately two hours. 

 “We think Ventripoint is a game-changer for children with heart disease,” said Beth Rumack, the Chief Operating Officer of the OHHF. “You no longer need to take a child down to an MRI suite, which entails a whole team of technicians and often means having to put the child under anesthesia, so they don’t move during the MRI scan. 

 “With Ventripoint, you just put a sensor on the child’s chest,” added Rumack, who is also a cardiac nurse practitioner and former hospital administrator. “You can do the scan in the child’s hospital room, even in a cardiologist’s office, and the results are available in minutes, not days. And you can take a scan safely, as often as you need.”  

 OHHF is bringing together 13 U.S. hospital partners into its Take Heart program, with 30 more expected to join, to promote new technologies and patient care approaches to heart health care, particularly for children and their families. It has selected three companies featuring AI technologies: Ventripoint, the clinical data software platform Etiometry, and the remote pediatric monitoring platform Locus Health. 

 “We want to introduce Ventripoint to all our hospital partners, to make it a standard of care,” said Rumack. “Ventripoint is the only AI technology like this in this category. There’s nobody else doing this. Their Artificial Intelligence approach to heart scans is pushing health care in a new direction, offering an inexpensive and rapid alternative to most MRI heart scans.” 

 Dr. Alvira Macanovic, Ventripoint’s President and CEO, welcomed the strategic partnership: “We are proud of the endorsement of the Ollie Hinkle Heart Foundation. OHHF aligns with Ventripoint’s core mission of helping patients with heart disease, as well as their families.  We are committed to furthering Ollie’s legacy by providing a less invasive and smarter treatment option. This partnership will advance the introduction of Ventripoint into U.S. hospitals.” 

 Jenn and Mark Hinkle, who lost their son to heart disease, are known for their advancement and funding of new technologies and innovative approaches to improving the care and outcomes for children facing heart disease. 

 "We're excited by the work being done at Ventripoint to advance the diagnostic capability and technology for the pediatric heart community,” said Jenn Hinkle. “Because Ollie had a pacemaker, he wasn't a candidate for an MRI. Had something like the VMS+ been around when Ollie was alive, his cardiac team would have had access to a clearer picture of what was going on with his heart during those critical moments leading up to his death, and his outcome may have been different.” 

 About Ventripoint Diagnostics Ltd. 

 Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada. 

 About the Ollie Hinkle Heart Foundation 

 Ollie Hinkle died due to congenital heart disease (CHD) at 13 months old. Mark and Jenn Hinkle channelled their grief into the Ollie Hinkle Heart Foundation (OHHF) by taking their love for Ollie and the love given to them by family and friends to pay it on to heart families whose struggles they knew first-hand. During Ollie’s life, the Hinkles observed the ineffective nature of cardiac care, which leaves families to endure and navigate mounting unmet needs alone. This experience led to a mission to transform the future of pediatric heart care by uniting families and clinicians to address basic social needs through Community Outreach, mental healthcare access through Ollie’s Branch, support for Technology and Research to improve outcomes, and collective community building through Take Heart. 

 For further information, please contact: 

 Jonathan Robinson 

 JRobinson@oakhillfinancial.ca   

 416-669-1001 

 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. 

 Forward Looking Statements 

 This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. 

 Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.